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Background: For HIV-serodiscordant couples, integrated delivery
of antiretroviral therapy (ART) for HIV-positive partners and time-
limited pre-exposure prophylaxis (PrEP) for negative partners
virtually eliminates HIV transmission. Standardized messaging,
sensitive to the barriers and motivators to HIV treatment and
prevention, is needed for widespread scale-up of this approach.
Methods: Within the Partners Demonstration Project, a prospective
interventional project among 1013 serodiscordant couples in Kenya
and Uganda, we offered ART to eligible HIV-positive partners and
PrEP to HIV-negative partners before ART initiation and through the
HIV-positive partner’s ﬁrst 6 months of ART use. We conducted
individual and group discussions with counseling staff to elicit the
health communication framework and key messages about ART and
PrEP that were delivered to couples.
Results: Counseling sessions for serodiscordant couples about
PrEP and ART included discussions of HIV serodiscordance, PrEP
and ART initiation and integrated use, and PrEP discontinuation.
ART messages emphasized daily, lifelong use for treatment and
prevention, adherence, viral suppression, resistance, side effects, and
safety of ART during pregnancy. PrEP messages emphasized daily
dosing, time-limited PrEP use until the HIV-positive partner
sustained 6 months of high adherence to ART, adherence, safety
during conception, side effects, and other risks for HIV.
Conclusions: Counseling messages for HIV-serodiscordant cou-
ples are integral to the delivery of time-limited PrEP as a “bridge” to
ART-driven viral suppression. Their incorporation into program-
matic scale-up will maximize intervention impact on the
global epidemic.
Key Words: counseling, pre-exposure prophylaxis, antiretroviral
treatment, couples, HIV-1 prevention, Africa
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BACKGROUND
HIV-serodiscordant couples, in which one partner is
HIV-positive and the other is HIV-negative, are estimated to
account for up to half of all new HIV infections in Africa and
are a priority population for HIV prevention interventions.1
Antiretroviral medications, used as antiretroviral therapy
(ART) and pre-exposure prophylaxis (PrEP), are potent
HIV prevention tools for HIV-serodiscordant couples.2–4
Current World Health Organization guidelines recommend
ART for all HIV-positive adults upon HIV diagnosis and
PrEP as part of combination HIV prevention for people with
substantial HIV risk, including HIV-negative partners of
serodiscordant couples.4
Although the HIV prevention efﬁcacy of ART and
PrEP is high, the prevention beneﬁts are only realized when
adherence is high.5,6 Counseling focused on risk reduction
and adherence to prevention tools is an essential component
of a comprehensive HIV prevention package, including
accompanying ART and PrEP delivery.7 Counseling mes-
sages that consider multiple levels of the social–ecological
model for health behavior have positively impacted HIV
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testing, successful linkage to HIV care and treatment, and
adherence to ART.8 Counseling sessions with trained staff
provide support for couples who are coping with HIV-
serodiscordancy, encourage engagement in HIV risk reduc-
tion, provide valuable information about HIV and routes of
transmission, and offer opportunities to identify and problem-
solve barriers to adherence.9,10
We recently demonstrated that an integrated delivery
package of PrEP and ART for HIV-serodiscordant couples in
Kenya and Uganda resulted in a 96% reduction in HIV
transmission, a level that was sustained after 2 years of
follow-up.11–12 In this approach, PrEP was recommended
until the HIV-positive partner initiated ART and was virally
suppressed, typically by 6 months after ART initiation.2,13 An
integral component of PrEP and ART delivery was counsel-
ing to educate participants about these medications and
explore their personal barriers to successful use of them.
Thus, we developed a counseling framework with under-
standable and scalable messages to be provided in counseling
sessions accompanying ART and PrEP delivery. Here, we
detail these messages so that they can accompany widespread
scale up of integrated PrEP and ART for HIV prevention
among HIV-serodiscordant couples.
METHODS
Study Design and Population
The Partners Demonstration Project was a prospective,
open-label implementation study of integrated ART and PrEP
delivery for HIV prevention at 4 research sites in Kenya
(Thika and Kisumu) and Uganda (Kampala and Kabwohe).
The project began in November 2012 and enrolled 1013
serodiscordant couples. To be eligible for enrollment, both
members of couples had to be aged $18, sexually active with
each other, and intending to remain together for at least 1
year. HIV-negative partners had normal renal function and
HIV-positive partners had not yet initiated ART. We used
a validated risk scoring tool to identify higher-risk couples for
this cohort with an expected annual HIV-1 incidence of .5%
in the absence of integrated delivery of PrEP and ART.14 A
majority of participants (94%) were married to each other and
14% of married men reported having more than one wife.
Couples were followed quarterly for 24 months (approxi-
mately 11 study visits per participant), were encouraged to
attend quarterly study visits together, and received couples-
based HIV prevention counseling.
Study Procedures
At enrollment, HIV-positive participants were coun-
seled to initiate ART in accordance with national guidelines,
which initially required a CD4 count of ,350 cells per
microliter or a clinical indication. In 2014, guidelines were
expanded to recommend use for all persons with negative
partners, regardless of clinical indications. HIV-positive
partners had CD4 and HIV viral load testing every 6 months.
At every visit, HIV-negative partners were tested for HIV
and offered a 3-month supply of PrEP medication [as
co-formulated emtricitabine (FTC)/(TDF)]. PrEP discontinu-
ation was encouraged once the HIV-positive partner had used
ART for 6 months. Although viral load was measured every 6
months and used to guide counseling when available,
counseling on PrEP continuation was not tied to these results
because viral load testing was not widely conducted and
would not be scalable in public health clinics. Adherence to
PrEP was.80% for expected doses taken and.90% of HIV-
positive partners that initiated ART achieved viral suppres-
sion within 6 months.11,15 PrEP use could extend beyond the
6 months overlap with ART use if couples reported ongoing
risk, including additional sexual partners, plans to attempt
pregnancy, or concern about the HIV-positive partner’s
adherence to ART.
PrEP and ART were delivered in the context of HIV-
serodiscordant couples counseling which used an adaptable,
client-centered approach for each couple. The duration and
depth of counseling discussions was responsive to the needs
of the couple and each individual but sessions were generally
30–45 minutes in length once every 3 months. Counseling
sessions were usually conducted by nurse counselors or
trained HIV prevention counselors, however, clinicians and
pharmacists also delivered the messages when appropriate.
As much as appropriate, couples were encouraged to attend
counseling sessions together to reap the beneﬁts of a having
neutral party hear concerns and challenges about HIV pre-
vention. Participants also met individually a counselor to
complete a behavioral questionnaire. Maintenance of partic-
ipant conﬁdentiality was a key counseling principle; when-
ever sensitive information (eg, additional partners, concerns
about partner ART adherence, or interpersonal violence) was
disclosed during behavioral questionnaires, counselors con-
ducted longer individual sessions, provided appropriate re-
ferrals, and used information to guide couple-level
recommendations including PrEP continuation. Recommen-
dations from counseling staff to prolong PrEP use were not
usually questioned by participants.9
Development of Counseling Messages
Phase I: Message Development
Our prior work with HIV-serodiscordant couples eli-
cited a great deal of information about barriers and motivators
to HIV treatment and prevention that informed the design of
the Partners Demonstration Project, the content of messages
used during counseling sessions in the project, and normative
guidelines for Couples HIV Counseling and Testing
(CHCT).16–25 In our previous study, HIV-positive partners
often had concerns about early ART initiation and did not
always accept clinician recommendations to initiate ART,
especially those aged ,25 years and those with higher CD4
counts (.250 cells per cubic millimeter).26 Stigma and fear
that ART initiation indicated HIV disease progression and
mortality were commonly cited barriers.22,27 For HIV-
serodiscordant couples, the dyad is an important construct
that can be leveraged for HIV prevention with members of the
couple providing important support to each other in daily pill
taking. In the Partners PrEP Study, HIV-negative members of
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serodiscordant couples demonstrated high adherence to PrEP
that may be understood as a function of the desire to reduce
their risk while preserving their relationship and maintaining
a sexual partnership.17 Many serodiscordant couples also
report barriers to condom use that are driven by men’s
preferences and misconceptions about serodiscordance.18
Additionally, many serodiscordant couples reported strong
desires to conceive that outweighed their fear of HIV
transmission and desire to use condoms.18,21 However, the
desire to conceive and prevent HIV transmission within the
partnership and to their infant also increased their motivation
to adhere to HIV prevention strategies.20,21,23,27
Informed by our previous work with couples, we
conducted a scientiﬁc literature review to further inform the
development of message content.3,17,20–23,26–30 We used
a conceptual framework that emphasizes the dyadic, contex-
tual conceptualization of HIV prevention behavior31 to ensure
the content of the messages addressed both individual and
relationship factors that could inﬂuence uptake of the
integrated strategy. Before the beginning of the Partners
Demonstration Project, we developed more than 80 standard-
ized messages to accompany the delivery of integrated PrEP
and ART. We trained approximately 30 Couples HIV
Counseling and Testing-experienced study counselors to
deliver the initial messages at all study visits.
Phase II: Message Reﬁnement
During the second year of the project, we began an
iterative process with study counseling staff delivering the
messages and intervention to deﬁne the content and pro-
gression of counseling sessions through messages related to
serodiscordance, ART, PrEP, and their integration and to
identify key, reﬁned messages using simple and accurate
language. We conducted group and individual discussions
with project counseling staff at each site to identify counsel-
ing topics and the messages most commonly used and of
greatest priority, messages that caused participant confusion,
common questions, and analogies used to frame the messages
to increase participant comprehension. We compared results
from these discussions across staff and sites to measure
consistency in messages that needed reﬁnement. We con-
ducted 4 iterations of reﬁnement that included editing to
ensure appropriateness for the cultural contexts.
Phase III: Message Validation
After each iteration of message reﬁnement, all project
staff were trained on the updated messages, used them with
participants, and provided additional feedback on participant
reactions to and comprehension of the messages. Addition-
ally, we consulted preliminary results of qualitative work that
was simultaneously being undertaken to understand partici-
pant preferences and experiences with PrEP and ART9,32 to
ensure that counseling staff experiences were consistent with
participant experiences. Before ﬁnalizing the messages, the
entire project team reviewed the package of messages and
made ﬁnal revisions.
RESULTS
Counseling Session Framework
Counseling sessions followed a framework to facilitate
couples understanding of 4 key topic areas: HIV serodiscord-
ance, ART use by the HIV-positive partner, PrEP use by the
HIV-negative partner, and the integration of time-limited
PrEP and ART to provide a couple with immediate and
sustained HIV prevention (Fig. 1). Counseling sessions most
often began with a comprehensive discussion of HIV
serodiscordance as it was often a confusing concept for
participants. Counseling staff emphasized the accuracy of
HIV tests, explained that serodiscordance can remain unrec-
ognized for years and did not necessarily indicate inﬁdelity,
and conﬁrmed that one partner could remain HIV-negative
despite maintenance of a sexual and loving relationship with
an HIV-positive partner.
FIGURE 1. Framework for counseling
HIV-serodiscordant couples about an
integrated PrEP and ART strategy.
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ART Messages
ART as HIV Treatment
Messages about the importance of ART use by the
HIV-positive partner of the couple were prioritized to both
members of the couple as a long-term strategy to treat and
prevent HIV (Fig. 2). Staff explained the important clinical
beneﬁts of ART for the HIV-positive person, addressed
concerns about daily pill taking, and mitigated beliefs that
ART initiation should be delayed until symptoms of AIDS
developed. ART was framed as a health preserving strategy.
HIV-positive partners were encouraged to begin ART as soon
as they were willing to reduce the risk for other illnesses and
improve overall health.
In addition to recommending immediate ART initiation,
daily ART adherence was encouraged without breaks.
Counseling staff assisted HIV-positive individuals to foresee
challenges with picking up their ART reﬁlls and identify
ways to overcome these challenges and avoid treatment
interruptions. ART adherence was also emphasized to protect
against selection of antiviral resistance. Counseling staff
explained that interruptions in ART use could result in the
development of resistance that would necessitate a change to
more complicated second-line ART regimens, which were not
always available.
ART as HIV Prevention
Counseling staff framed the HIV prevention beneﬁts of
sustained ART use with high adherence as a commitment to
the relationship and the HIV-negative partner. Because under-
standing treatment as prevention was a challenging concept for
most participants, counseling staff developed an analogy to
liken ART to an army that was engaged to combat HIV. First,
they explained the continuous replication of HIV, measured in
blood as “viral load.” Then, they described the role of viral
load in HIV transmission and how ART reduces viral load,
resulting in viral suppression, and thus virtually eliminates risk
of HIV transmission. HIV-positive partners were told that it
typically takes 3–6 months of daily ART use to decrease the
amount of HIV in their blood to a nontransmissible level.
Pregnancy and ART Use
For couples with pregnancy intentions, counseling staff
explained that ART is safe to use during peri-conception,
pregnancy, and breastfeeding and that it will not reduce the
couple’s ability to safely conceive children. HIV-positive
women were encouraged to initiate ART before pregnancy to
optimize their prepregnancy health, decrease their viral load,
and establish a routine with ART use. Messages also
emphasized the role of ART to prevent HIV transmission to
their babies throughout pre-pregnancy and postpartum.
PrEP Messages
PrEP Use as HIV Prevention
Counseling sessions focused on how to use PrEP as an
HIV prevention tool for men and women (Fig. 3). Counseling
staff emphasized that PrEP is not a life-long intervention,
unlike ART, but that it should be used during periods with
greatest HIV risk. They encouraged continuous personal risk
assessment to identify situations of risk when the option of
prolonging PrEP use was most beneﬁcial, including times
before the HIV-positive partner had achieved viral suppres-
sion, when the couple was attempting pregnancy, and when
there were outside risks of HIV transmission from other
partners whose HIV status or ART status was unknown.
Appropriate PrEP Use
Messages stressed the importance of taking PrEP every
day to confer protection from HIV and that missed PrEP doses
FIGURE 2. ART messages.
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could render someone vulnerable to HIV infection. Participants
were counseled to test for HIV every 3 months to conﬁrm their
HIV negative status with additional testing recommended if
they suspected that they might be HIV infected. Counseling
staff described drug resistance and emphasized that taking
PrEP doses while HIV infected could lead to drug resistance,
restating the importance of regular testing.
In strategizing with participants about how to attain
high medication adherence, counseling staff clariﬁed mis-
conceptions that equated PrEP with a one-time delivered
vaccine or beliefs that it can provide protection when only
taken after sex. Counseling staff normalized the challenges of
high adherence, including stigma of being mistakenly per-
ceived to be HIV positive, travel, or new partners and stressed
the importance of identifying strategies to overcome these
challenges. Counseling staff also reassured participants that
PrEP can be taken without food.
Pregnancy and PrEP Use
HIV-negative women attempting pregnancy were
counseled on the increased risk of HIV transmission during
pregnancy and that PrEP is safe to use when they were
trying to conceive. Women who became pregnant while
using PrEP were encouraged to consider the risks and
beneﬁts of continuing PrEP use during pregnancy, includ-
ing the risk of HIV acquisition if they discontinued PrEP
during pregnancy.33
Commonalities in PrEP and ART Messages
To assist participant understanding and prevent confu-
sion, concepts that overlapped in PrEP and ART use were
presented using similar language and analogies. For example,
counseling staff encouraged all participants to establish
a routine time of day for taking their medication, such as
a meal time or during a favorite radio show. Participants were
encouraged to use cell phone reminders or to ask a friend or
their partner to help them remember to take their medication.
Counseling staff encouraged participants planning to travel to
ensure they had sufﬁcient pills and to keep pills safe in
smaller containers for compactness and to avoid drawing
attention to the pill bottle.
Participants were frequently concerned they would
experience side effects. To minimize fear of side effects,
counseling staff explained that all medications have side
effects which manifest in each person differently and that side
effects to antiretroviral medications are often minimal and
lessen after the ﬁrst 1–2 months of consistent use.
Counseling staff emphasized condom use as an impor-
tant part of combination prevention and encouraged all
participants to use condoms to prevent against sexually
transmitted infections and unintended pregnancy. Explanations
of the synergistic effects of combination prevention often
required additional explanation so counseling staff would
provide culturally relevant analogies to help participants
understand how condoms work in tandem with PrEP and
ART. One such analogy explained that home owners often use
multiple forms of security including locks on doors, perimeter
walls, and security guards, and that all of these measures work
together to protect the home owners from theft and violence.
Similarly, one can use ART, condoms, and PrEP to maximize
protection against HIV transmission. Because of the overlap in
some messages, counselors took care to emphasize and ensure
participants’ understanding of the unique difference between
the medications—speciﬁcally, that ART provides lifelong
prevention, whereas PrEP is a time-limited prevention inter-
vention insufﬁcient to treat HIV infection. Messages were
reinforced when necessary to correct any misinformation and
ensure continued understanding.
FIGURE 3. PrEP messages.
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Counseling Messages for the Integrated
Delivery of ART and PrEP
Beginning with ﬁrst contact with participants and
continuing through follow-up, counseling staff explained
the integrated use of ART and time-limited PrEP (Fig. 4).
Both partners were encouraged to use their respective
antiretroviral medications, not to share their medications,
and to support each other’s adherence. When the HIV-
positive partner delayed ART initiation, counseling staff
emphasized the importance of high adherence to PrEP to
reduce their HIV risk. Once the HIV-positive partner initiated
ART, future PrEP discontinuation became a central theme of
counseling sessions with counseling staff encouraging PrEP
discontinuation after the HIV-positive partner used ART for 6
months, the period of time by which ART would achieve viral
suppression. Discussions of PrEP discontinuation often
focused on reassuring couples of the effectiveness of ART
use by the HIV-positive partner. If either partner expressed
concern about viral suppression or the HIV-positive partner’s
ART adherence, counseling staff could suggest that PrEP be
continued for a short period (often extending PrEP for
a month at a time). Additionally, counseling staff encouraged
PrEP continuation regardless of ART use by the HIV-positive
partner if HIV-negative participants disclosed ongoing HIV
risk, such as additional partners of unknown HIV/ART status
during individual and couples’ counseling sessions.
CONCLUSIONS
To accompany the delivery of integrated PrEP and ART
for HIV prevention among HIV-serodiscordant couples, coun-
selors highly experienced in working with HIV-serodiscordant
couples identiﬁed a framework and the team developed and
reﬁned key messages to encourage PrEP use by HIV-negative
partners as a “bridge” to sustained ART use by the HIV-
positive partner. Each message maps to a common participant
concern.9,32 The general ﬂow of counseling topics moved
from HIV serodiscordance to the purpose of ART use for
treatment and prevention, how PrEP works to prevent
infection, and how the 2 strategies can work together.
Counselors conveyed conﬁdence in the strategies, probed
for participant comprehension, and provided responses to
outstanding questions. Counseling sessions used a pragmatic
approach that minimized burden on the providers and
participants and can be delivered by the cadre of lay and
professional staff (eg, HIV prevention counselors and nurse
counselors) already providing HIV prevention counseling in
Kenya and Uganda.
In our work, as well as other studies among HIV-
serodiscordant couples, the process for couples to understand
and accept their HIV-serodiscordant status was complex,
requiring time and message repetition during multiple
counseling sessions.19 When couples learned that they were
in a serodiscordant relationship, they were often confused and
unsure if their relationship was sustainable.9 Client-centered
counseling supports the couple by giving them a non-
stigmatizing space to understand HIV serodiscordance,
explore how their different HIV statuses affect their commit-
ment to each other and the future of their relationship, and
identify barriers and facilitators to adopting HIV prevention
behaviors. During these sessions, counseling staff can initiate
discussions about integrated PrEP and ART as prevention
options that often meet couples’ short- and long-term needs.
Although the study was not designed to measure the
impact of the messages separately from the delivery of
integrated PrEP and ART, the framework and accompanying
messages were developed to help couples understand how
antiretroviral-based HIV prevention works. Participants
beneﬁtted from the use of analogies and concise, easy to
understand messages to secure their understanding of how
ART provides a beneﬁt for both partners and how PrEP
provides protection against HIV. Although both partners are
taking antiretroviral-based medications, the messages helped
counseling staff nurture understanding of how and why PrEP
is used as a bridge to effective ART use by the HIV-positive
partner, permitting time for both partners to gain conﬁdence
in viral suppression as an effective and sufﬁcient HIV
prevention strategy and thereby also preparing them for PrEP
discontinuation. PrEP as a bridge to ART is an extremely
effective HIV prevention strategy11–12; the messages were
essential to foster understanding and trust that high adherence
to the medications prevents HIV transmission.9
FIGURE 4. Messages about the integration of
PrEP and ART.
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Couples-based counseling incorporating both partners
proved beneﬁcial for HIV prevention discussions, including
conversations about ART use by the positive partner and
PrEP use by the HIV-negative partner. Counseling sessions as
a dyad allowed the couple to learn together about HIV,
discuss challenges and beneﬁts of ART use with high
adherence, and be encouraged to mutually support each
other’s medication taking. Importantly, these counseling
sessions also provide the HIV-negative partner a valuable
place to receive support and openly express concerns about
HIV risk, including concerns about the positive partner’s
adherence. Additionally, continued counseling sessions for
the couple together and the HIV-negative person alone
provide a space for the couple to raise concerns about new
sources of risk (eg, interruptions in ART use or new partners)
that may indicate re-initiation of PrEP.
Our results are somewhat limited because we did not
use a formal development process to create the messages and
we did not measure ﬁdelity. However, counseling was an
integral component of the highly successful program. Fur-
thermore, messages were developed and reﬁned by a highly
experienced counseling staff and responded to concerns
participants raised in ancillary qualtitative interviews.9,32
The framework and messaging could be strengthened by the
use of more formal qualitative research or pilot studies to
fully test the utility of these speciﬁc messages. In addition,
because study participants had very high adherence to both
PrEP and ART and couples were only followed for 24
months, messaging about PrEP re-initiation did not emerge as
a priority. Future efforts to understand the longevity of use of
ART and PrEP in serodiscordant couples would be useful.
Finally, many of these messages are relevant for other high
risk populations, such as young women, and warrant
additional testing among these groups.
The delivery of ART to HIV-positive partners inte-
grated with time-limited PrEP use by HIV-negative partners
is a highly effective and cost efﬁcient strategy for HIV-
serodiscordant couples.34 Plans for PrEP delivery to HIV-
serodiscordant couples are being developed and implemented
in place in multiple settings. The counseling framework and
accompanying messages used during this demonstration
project can be adopted by each program and tailored for the
programmatic context to maximize intervention impact on the
global epidemic.
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